INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

  • Jumpstart Cell & Gene Therapy Commercialization With SUT Learning
    Jumpstart Cell & Gene Therapy Commercialization With SUT Learning

    Single use technologies are expected to play a big role in the commercialization of cell and gene therapies because of their cost, speed, and sterility benefits. In some ways,  will cell and gene therapy manufacturing be similar to biopharmaceutical manufacturing? What are the key differences and gaps in learning?

  • The Right Upstream Bioreactor Techn For Industrial Scale Viral Manufacturing
    The Right Upstream Bioreactor Techn For Industrial Scale Viral Manufacturing

    Solving the bottleneck in gene therapy of manufacturing of viral material at sufficient cost and scale.

  • New Microbiological Methods In Bioprocessing
    New Microbiological Methods In Bioprocessing

    Testing for evidence of microbial contamination in bioprocessing has a long history — and can be expensive, slow, and burdensome. So suppliers, testing facilities, and regulators have been seeking improvements.

  • When Is Virtual The Right Course Of Action?
    When Is Virtual The Right Course Of Action?

    A look at three scenarios that may impact the decision of virtual or in-house manufacturing, as well as key aspects to consider in the selection process and in forming a strong relationship between the company and CDMO.

  • Intricate Supply Chain Complicates Gene Therapy Manufacturing
    Intricate Supply Chain Complicates Gene Therapy Manufacturing

    With the FDA’s approval of three new gene therapies, researchers and manufacturers must now figure out how streamline the development process.

  • Japan Pharma: Top Tier With Tons Of Opportunity
    Japan Pharma: Top Tier With Tons Of Opportunity

    Opportunities related to the world’s third largest pharma industry tend to get drowned out by U.S. domestic events, and news from Europe, China, and even India. But if you haven’t been, it’s time to start paying attention to Japan again. There are opportunities for partnering, providing services to Japan Pharma, and for market penetration by foreign biopharma companies.

  • Deal Building From Testing The Water To Hitting The Market
    Deal Building From Testing The Water To Hitting The Market

    The story of how Oxford BioMedica won a key contract from Novartis to provide the commercial and clinical supply of lentiviral vectors used to produce the Big Pharma's CAR-T cell therapy Kymriah.

  • The Intriguing Origins Of A Gene Therapy Biopharma
    The Intriguing Origins Of A Gene Therapy Biopharma

    An inside look into how this fledgling biopharma has raised over $150 million and enlisted two high-profile CEOs from one of the hottest VC firms around, all in less than two years.

  • 4 Steps For Successful Tech Transfer Of Gene And Cell Therapy Products
    4 Steps For Successful Tech Transfer Of Gene And Cell Therapy Products

    As the gene and cell therapy sector develops and its products start to move from development to commercial manufacture — from smaller or academic establishments and development laboratories to larger facilities with greater capacity — the requirement for the technology transfer of these products will only increase.

  • The Emergence Of New Gene Therapy Hubs
    The Emergence Of New Gene Therapy Hubs

    With gene therapy, we are at the dawn of another era of potentially rapid growth in the sector. And companies planning for their futures will once again consider a range of factors in identifying the optimal locations for gene therapy research and production centers.

More On Outsourcing Issues